Association and Risk Factors of Healthcare-associated Infection and Burden of Illness Among Chemotherapy-induced Ulcerative Mucositis Patients

Overview

Journal Clin Oral Investig

Specialty Dentistry

Date 2021 Aug 6

PMID 34355291

Citations 1

Authors

P S Satheeshkumar

M P Mohan

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate the association and risk factors of healthcare-associated infection (HAI) and burden of illness among chemotherapy-induced ulcerative mucositis (UM) patients.

Methods: For this research, US National Inpatient Sample database 2017 was utilized to study UM patients. The association of healthcare-associated infection-related burden of illness among UM patients was assessed on the outcome--length of hospital stays (LOS), total charges, in-hospital mortality, and discharge disposition.

Result: In 2017, there were 11,350 adult (> 18 years of age) UM patients, among them there were 415 (3.5%) HAI. After adjusting for patient and clinical characteristics, UM patients with HAI were most likely to have higher total charges and longer LOS (1.91; 95% CIs: 1.51-2.41; P < 0.001; 1.84; 95% CIs: 1.53-2.21; P < 0.001) than those without HAI. Further, mortality was not significantly different. UM patients with HAI were less likely to have higher burden of illness who were younger, females, those living in non-metropolitan or micropolitan counties, and those with lower co-morbidity score. Additionally, UM patients with HAI were more likely to discharge to skilled nursing facility (SNF), intermediate care facility (ICF), and another type of facility (ATF), (aOR = 2.58 (1.16-5.76), P = 0.02), than they were to discharge to self-care or home care.

Conclusion: UM patients with HAI were more likely to have higher burden of illness and more likely to discharged to the SNF, ICF, and ATF rather than to home or self-care. Clinical relevance UM patients when associated with HAI have higher burden of illness; a tailored approach to oral care might prevent HAIs and burden of illness among UM.

Citing Articles

Cancer treatment-induced ulcerative mucositis serves as a significant predictor of burden of illness including dysphagia, and associated disparities among hospitalized cancer patients.

Mohan M, Pili R, Epstein J, Rudin L, Eichhorn S, Satheeshkumar P Support Care Cancer. 2024; 33(1):22.

PMID: 39666090 DOI: 10.1007/s00520-024-09071-4.

References

Lalla R, Sonis S, Peterson D . Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2007; 52(1):61-77, viii. PMC: 2266835. DOI: 10.1016/j.cden.2007.10.002. View

Berger K, Schopohl D, Bollig A, Strobach D, Rieger C, Rublee D . Burden of Oral Mucositis: A Systematic Review and Implications for Future Research. Oncol Res Treat. 2018; 41(6):399-405. DOI: 10.1159/000487085. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Wang E, Chen Y, Corringham S, Bashey A, Holman P, Ball E . High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant. 2004; 34(7):581-7. DOI: 10.1038/sj.bmt.1704637. View

Elting L, Keefe D, Sonis S, Garden A, Spijkervet F, Barasch A . Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008; 113(10):2704-13. DOI: 10.1002/cncr.23898. View

Pfister D, Spencer S, Brizel D, Burtness B, Busse P, Caudell J . Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015; 13(7):847-55. PMC: 4976490. DOI: 10.6004/jnccn.2015.0102. View

Lalla R, Saunders D, Peterson D . Chemotherapy or radiation-induced oral mucositis. Dent Clin North Am. 2014; 58(2):341-9. DOI: 10.1016/j.cden.2013.12.005. View

Carlotto A, Hogsett V, Maiorini E, Razulis J, Sonis S . The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics. 2013; 31(9):753-66. DOI: 10.1007/s40273-013-0081-2. View

Dodd M, Dibble S, Miaskowski C, Paul S, Cho M, MacPhail L . A comparison of the affective state and quality of life of chemotherapy patients who do and do not develop chemotherapy-induced oral mucositis. J Pain Symptom Manage. 2001; 21(6):498-505. DOI: 10.1016/s0885-3924(01)00277-9. View

10.

Cornejo-Juarez P, Vilar-Compte D, Perez-Jimenez C, Namendys-Silva S, Sandoval-Hernandez S, Volkow-Fernandez P . The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. Int J Infect Dis. 2014; 31:31-4. DOI: 10.1016/j.ijid.2014.12.022. View

11.

Barkokebas A, Silva I, de Andrade S, Carvalho A, Alcino Monteiro Gueiros L, Martins Paiva S . Impact of oral mucositis on oral-health-related quality of life of patients diagnosed with cancer. J Oral Pathol Med. 2014; 44(9):746-51. DOI: 10.1111/jop.12282. View

12.

Cheng K, Lee V, Li C, Yuen H, Ip W, He H . Impact of oral mucositis on short-term clinical outcomes in paediatric and adolescent patients undergoing chemotherapy. Support Care Cancer. 2013; 21(8):2145-52. DOI: 10.1007/s00520-013-1772-0. View

13.

Elting L, Cooksley C, Chambers M, Garden A . Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007; 68(4):1110-20. DOI: 10.1016/j.ijrobp.2007.01.053. View

14.

Nonzee N, Dandade N, Patel U, Markossian T, Agulnik M, Argiris A . Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received.... Cancer. 2008; 113(6):1446-52. DOI: 10.1002/cncr.23714. View

15.

Sampson M, Nanjappa S, Greene J . Mucositis and oral infections secondary to gram negative rods in patients with prolonged neutropenia. IDCases. 2017; 9:101-103. PMC: 5512178. DOI: 10.1016/j.idcr.2017.06.014. View

16.

Sotiropoulos S, Jackson M, Woods G, Hicks R, Cullen J, Freeman A . Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside. Pediatr Infect Dis J. 1989; 8(11):755-8. DOI: 10.1097/00006454-198911000-00005. View

17.

Burden A, Oppenheim B, Crowther D, Howell A, Morgenstern G, Scarffe J . Viridans streptococcal bacteraemia in patients with haematological and solid malignancies. Eur J Cancer. 1991; 27(4):409-11. DOI: 10.1016/0277-5379(91)90373-l. View

18.

Elixhauser A, Steiner C, Harris D, Coffey R . Comorbidity measures for use with administrative data. Med Care. 1998; 36(1):8-27. DOI: 10.1097/00005650-199801000-00004. View

19.

Bland J, Altman D . Transformations, means, and confidence intervals. BMJ. 1996; 312(7038):1079. PMC: 2350916. DOI: 10.1136/bmj.312.7038.1079. View

20.

Battaglia C, Hale K . Hospital-Acquired Infections in Critically Ill Patients With Cancer. J Intensive Care Med. 2018; 34(7):523-536. DOI: 10.1177/0885066618788019. View